FDA Clears Neuroblade System for Minimally Invasive Neurosurgery

Clearmind Biomedical has won U.S. Food and Drug Administration (FDA) 510(k) clearance for its Neuroblade System.

The neuroendoscopy system enables minimally invasive procedures with integrated features such as visualization, illumination, irrigation, suction, coagulation, and powered debridement. The Neuroblade System made its U.S. OR debut at Mt. Sinai Hospital in New York City under the guidance of neurosurgeon Dr. Christopher Kellner. “The Neuroblade system offers a valuable new tool for the surgical management of intracerebral hemorrhage,” Dr. Kellner said. “Its minimally invasive design streamlines the operating room setup and integrates essential functions into a single handpiece, potentially improving patient outcomes. The Neuroblade system represents a new class of technology that should simplify neurosurgical procedures and provide patients a chance at more favorable outcomes.”

The Neuroblade System is composed of three components: the Neuroblade, a single-use multifunctional neuroendoscope; the Neuropad, a reusable medical-grade tablet; and Clearpath, a disposable transparent access sheath. This system is designed to improve the efficiency and outcomes of minimally invasive neurosurgical procedures.

Dr. Kellner employed the Neuroblade system during an urgent procedure to evacuate a hemorrhagic stroke. The Clearpath sheath allowed precise access to the target area, while the Neuroblade provided an all-in-one instrument with real-time visualization and integrated tools for suction, irrigation, powered debridement, and coagulation.
​
“FDA clearance and the first U.S. surgery mark significant milestones for the Neuroblade System, which we believe will revolutionize minimally invasive neurosurgery,” Clearmind Biomedical Vice President/General Manager for the Americas J. Dustin Duckett stated. “Developed with input from surgeons, Neuroblade’s integrated features aim to enhance surgical efficiency and patient outcomes. We look forward to further developing evidence, driving adoption, and ultimately getting more patients access to desperately needed care.”
​
Clearmind Biomedical is a privately held medical device company based in San Jose, Calif., and Taipei, Taiwan. The company has developed a portfolio of minimally invasive devices aimed at improving care for neurosurgery patients. Clearmind has filed 21 patents and completed multiple studies to support the clinical value of the Neuroblade system.